Printer Friendly

MEDCO RESEARCH TO RELOCATE OPERATIONS

 LOS ANGELES, March 4 /PRNewswire/ -- Medco Research, Inc. (AMEX: MRE) in a letter to shareholders today, announced that its board of directors approved a plan under which the company would move its operations from Los Angeles to Research Triangle Park, North Carolina. Medco expects to complete the relocation by the end of 1993.
 "The Research Triangle Park area is one of the most dynamic centers for pharmaceutical development in the world," said Archie W. Prestayko, president and chief executive officer of Medco. "As such, it is a particularly fertile environment for Medco, and an attractive location for us as we recruit scientific and managerial talent commensurate with our growth. We believe that the move to this area will be very helpful to controlling Medco's operating costs and therefore will be consistent with the increased focus on cost containment required for health care reform in the United States."
 The shareholder letter also reported on a recent Medco-sponsored clinical investigator workshop on its product, IPPA, a nuclear imaging agent, attended by more than forty nuclear cardiologists and nuclear medicine physicians. The participants discussed methods used in the detection of viable "hibernating" heart muscle and the ability to predict the potential benefit of various surgical and other revascularization procedures in patients with severe heart disease. The meeting also focused on the design of IPPA's Phase III multicenter clinical trials, which are planned to begin in late 1993 pending successful completion of the current Phase II trials.
 With respect to the status of Adenoscan, Dr. Prestayko added, "Fujisawa USA, our manufacturing and marketing licensee for this product, has manufactured one commercial lot of Adenoscan at its modernized facility in Grand Island, N.Y., and has delivered a portion of this lot to our clinical supplies distributor for shipment to our clinical investigators. Fujisawa has advised Medco that this lot passed new internal release specifications and that two additional commercial batches of Adenoscan are currently in production."
 Medco Research is a pharmaceutical company engaged in the acquisition, research and development of new prescription drugs for the diagnosis or treatment of certain cardiovascular diseases and cancer.
 -0- 3/4/93
 /CONTACT: Archie W. Prestayko, Ph.D. of Medco Research, Inc., 213-966-4148, or Fredric J. Spar of Kekst and Company, 212-593-2655, for Medco Research, Inc./
 (MRE)


CO: Medco Research, Inc. ST: California IN: MTC SU:

TS -- NY012 -- 2803 03/04/93 08:55 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 4, 1993
Words:397
Previous Article:MILAN PANIC RETURNS TO ICN PHARMACEUTICALS
Next Article:Note to the Editor: The following information may be of use in covering the response to the Feb. 26, 1993, bombing at the World Trade Center.
Topics:


Related Articles
MEDCO RESEARCH ANNOUNCES APPOINTMENT OF EUGENE STEP TO BOARD OF DIRECTORS
MEDCO RESEARCH REPORTS TRANSITION PERIOD FINANCIAL RESULTS
MEDCO RESEARCH FILES COMPLAINT AGAINST FUJISAWA PHARMACEUTICAL CO.
MEDCO RESEARCH'S ADENOCARD APPROVED IN CANADA
MEDCO RESEARCH REPORTS FIRST QUARTER FINANCIAL RESULTS
MEDCO SIGNS BIDILTM MARKETING OPTION AGREEMENT WITH BOEHRINGER MANNHEIM PHARMACEUTICAL COMPANY
MEDCO RESEARCH NAMES DIRECTOR, RADIOPHARMACEUTICAL CLINICAL RESEARCH
MEDCO RESEARCH REACHES ADENOSCAN MANUFACTURING AGREEMENT WITH ABBOTT LABORATORIES
FUJISAWA USA PREPARES FOR ADENOSCAN(R) APPROVAL, PURSUES COMPLAINT AGAINST MEDCO RESEARCH AND ABBOTT
MEDCO RESEARCH APPOINTS ANNE MCKAY DIRECTOR OF REGULATORY AFFAIRS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters